John, B7H3 is a surface protein very prevalent in aggressive PCa.
So far, there is no specific immunotherapy that targets it, but the literature calls it ‘promising’.
From a quick search there is a LOT of interest right now but I couldn’t find any ongoing clinical trials. Hope this helps.
Phil
John, B7H3 is a surface protein very prevalent in aggressive PCa.
So far, there is no specific immunotherapy that targets it, but the literature calls it ‘promising’.
From a quick search there is a LOT of interest right now but I couldn’t find any ongoing clinical trials. Hope this helps.
Phil
GSK has received breakthrough approval for small cell lung, cancer and osteosarcoma. Don’t see why prostate cancer shouldn’t be next on the list since aggressive cases exhibit such high amounts of the surface protein.🤞
John, B7H3 is a surface protein very prevalent in aggressive PCa.
So far, there is no specific immunotherapy that targets it, but the literature calls it ‘promising’.
From a quick search there is a LOT of interest right now but I couldn’t find any ongoing clinical trials. Hope this helps.
Phil
Thanks Phil,
This might be the trial:
https://clinicaltrials.gov/study/NCT06551142
GSK has received breakthrough approval for small cell lung, cancer and osteosarcoma. Don’t see why prostate cancer shouldn’t be next on the list since aggressive cases exhibit such high amounts of the surface protein.🤞